Issues

Intratumoral vidutolimod (CpG-A TLR9 agonist) together with pembrolizumab overcomes PD-1 blockade resistance in 25% of patients with metastatic melanoma with manageable toxicities in a phase I trial.

Analysis of data from the Genomes for Kids research study reveals the value of three-platform whole-genome, wholeexome, and RNA sequencing in identifying clinically and biologically relevant lesions in pediatric cancer.

AKT depletion using a degrader proved superior to kinase inhibition due to sustained repression of AKT signaling and destabilization of AURKB, leading to induction of G2/M arrest, hyperploidy, and cell death.

Reactivation of p53 by MDM2 inhibitors potentiates anticancer immune surveillance through derepression of ERVs and dsRNA stress, resulting in induction of the interferon pathway and improved response to checkpoint therapy.

Genetic screening in a mouse model of biliary cancer revealed Pik3ca^H1047R activation but not oncogenic Kras^G12D as critical for transformation and tumor formation and additionally reveals the context- and tissue-specific nature of oncogenic drivers.

Inhibition of a specific isoform of RON receptor tyrosine kinase (SF-RON) recruits stemlike CD4 T cells to the metastatic site and promotes strong antitumor immune responses that severely restrict growth of breast cancer metastases.

Oncogenic NPM1c mutations prime acute myeloid leukemia cells for mitochondrial targeting by actinomycin D, which restores PML nuclear bodies—driven senescence and is synergistic with venetoclax to induce tumor clearance.